ERBB2 and breast cancer: They also reveal that the FOXD3/BRD4/miR-548d-3p axis is highly activated in BLBC cells, which explains the lower JunD/RSK3 levels and higher sensitivity to BET inhibition of BLBC cells compared with luminal and HER2+ breast cancer cells.